Related Experiment Videos
[Anticoagulation in cardiac pathologies (except atrial fibrillation)]
1Département de Cardiologie, C.H.U. Tivoli, La Louvière, U.L.B.
Revue Medicale De Bruxelles
|October 19, 1999
Summary
Anticoagulant therapies, like heparins and antivitamins K, are crucial in cardiology. New uses are emerging, but careful benefit-risk assessment is vital for conditions like valvular prosthesis and dilated cardiomyopathy.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Anticoagulants, including heparins and vitamin K antagonists, are widely used in cardiovascular medicine.
- Established treatment guidelines exist, but new indications are continually emerging.
- The role of anticoagulation in various cardiac conditions requires ongoing evaluation.
Purpose:
- To review current and emerging indications for anticoagulant therapy in cardiology.
- To emphasize the importance of benefit-risk assessment in prescribing anticoagulants.
- To provide guidance on anticoagulant use in specific cardiac conditions.
Summary:
- Oral anticoagulants significantly reduce thromboembolic risk in patients with cardiac valvular prostheses.
- For non-operated valvulopathy, anticoagulant indication requires individualized benefit-risk evaluation.
- Anticoagulant prescription in dilated cardiomyopathy should be restricted to high-embolic-risk patients.
- Indications beyond atrial fibrillation necessitate careful consideration.
Impact:
- Informs clinical decision-making regarding anticoagulant use in complex cardiac cases.
- Highlights the need for personalized medicine approaches in cardiovascular pharmacotherapy.
- Contributes to optimizing patient outcomes by managing thromboembolic risks effectively.